semaglutide bruise at injection site Bruising: A Neglected, Though Patient-Relevant Complication of Insulin Injections Coming to Light from a Real-Life Nationwide First injection - horrible bruise?

FDA-approved GLP-1 agonist labels explicitly warn against co-administration with other GLP-1 agonists

Due to Americas obesity epidemic, more individuals are now turning towards medical interventions such as semaglutide combined with lifestyle modifications for better health outcomes and for an improved overall wellbeing

10.2337/db12-0364 92 KaulR

Recent evidence supports the use of GLP-1 RAs in patients with obesity-related HFpEF

Treatment with SOD has experimentally been shown to reduce liver oxidative stress in diabetic animals.[79] SOD mimetic (Mn[II][pyane] Cl2) has successfully been used to treat diabetes in diabetic rats.[80] Chemically modified SOD (carboxymethylcellulose-SOD and poly methyl vinyl ether-co-maleic anhydride-SOD) was effective in treating diabetes and offers a therapeutic advantage in clinical use.[81] It has been demonstrated that extracellular SOD can act as a therapeutic agent to protect the progression of diabetic nephropathy.[82] Current limitations of SODs for therapeutic applications Due to the instability, high immunogenicity, low cellular uptake, and lesser circulation in vivo half-life of SOD, their clinical applications as therapeutic agents are very limited